Text Size

Behavioral Therapy Development for Methamphetamine Abusers

This study has suspended participant recruitment.
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Steve Shoptaw, University of California, Los Angeles
ClinicalTrials.gov Identifier:
NCT00249678
First received: November 3, 2005
Last updated: May 31, 2013
Last verified: May 2013
History of Changes
  Purpose

The purpose of this study is...to assess whether placing a substance abuse intervention for HIV+ methamphetamine users within an HIV medical care setting improves rates of follow-up on referral to treatment by primary care physicians; reduces drug use and sexual risk behaviors more than treatment-as-usual; and increases rates of adherence to HIV medication regimens.


Condition Intervention Phase
The Study Was Designed to Develop a Cognitive Behavioral Approach to Treating Methamphetamine Abuse in HIV Primary Care Settings.
 Behavioral: Behavior Therapy
 Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Behavioral Therapy Development for Methamphetamine Abuse

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of California, Los Angeles:

Primary Outcome Measures:
  • Craving
  • Medication compliance
  • Addiction severity
  • Psychiatric interview
  • Sex-risk behavior

Secondary Outcome Measures:
  • Depression
  • Quality of Life

Estimated Enrollment: 50
Study Start Date: September 2004
Estimated Study Completion Date: May 2007
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. HIV-seropositive, GBM receiving medical treatment for HIV for at least 30 days prior to signing informed consent at the UCLA CARE clinic, aged 18-65
  2. Willing to give informed consent and comply with study procedures;
  3. Willing to provide consent to contact treating physicians and pharmacies to assess adherence to HIV medications;
  4. Diagnosed with current methamphetamine abuse as determined by MINI; and
  5. Interested in seeking treatment for their methamphetamine abuse and in participating in this research project.

Exclusion Criteria:

  1. Unwilling to give, or withdrawal of, informed consent;
  2. Inability to understand nature of study;
  3. A psychiatric condition that, in the principal investigator's judgment, warrants additional intervention to ensure participant safety (e.g., meets DSM-IV-TR criteria for current bipolar disorder or a psychotic disorder);
  4. Current suicidal ideation or suicide attempt within the past 3 months; and
  5. Concurrent dependence on opiates, alcohol, or benzodiazepines as determined by MINI.
  6. Total lack of any type of healthcare coverage. These potential participants will be given low-fee treatment referrals.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00249678

Locations
United States, California
UCLA CARE Clinic
Los Angeles, California, United States, 90035
UCLA Medical Center
Los Angeles, California, United States, 90024
UCLA, Integrated Substance Abuse Programs
Los Angeles, California, United States, 90024
Sponsors and Collaborators
University of California, Los Angeles
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: James Peck, Other University of California, Los Angeles
  More Information

No publications provided

Responsible Party: Steve Shoptaw, Professor, University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT00249678     History of Changes
Other Study ID Numbers: NIDA-18075-1, R21DA018075, R21-18075-1
Study First Received: November 3, 2005
Last Updated: May 31, 2013
Health Authority: United States: Federal Government

Keywords provided by University of California, Los Angeles:
Behavior Therapy
methamphetamine

Additional relevant MeSH terms:
Methamphetamine
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Dopamine Agents
Neurotransmitter Agents
 Molecular Mechanisms of Pharmacological Action
Central Nervous System Stimulants
Central Nervous System Agents
Therapeutic Uses
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Dopamine Uptake Inhibitors

ClinicalTrials.gov processed this record on June 17, 2013